Ursula Haak

694 total citations
4 papers, 448 citations indexed

About

Ursula Haak is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Ursula Haak has authored 4 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pathology and Forensic Medicine, 2 papers in Genetics and 2 papers in Oncology. Recurrent topics in Ursula Haak's work include Lymphoma Diagnosis and Treatment (4 papers), Viral-associated cancers and disorders (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Ursula Haak is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), Viral-associated cancers and disorders (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Ursula Haak collaborates with scholars based in Germany. Ursula Haak's co-authors include C. Klinkenstein, Robert Rohrberg, Haifa Kathrin Al‐Ali, Andreas Neubauer, Sabine Neser, Ralph Naumann, E. Kettner, Antje Haas, Stefanie Srock and Mathias Freund and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia & lymphoma.

In The Last Decade

Ursula Haak

4 papers receiving 438 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ursula Haak Germany	2	413	280	229	59	55	4	448
C. Klinkenstein Germany	2	344 0.8×	258 0.9×	177 0.8×	46 0.8×	58 1.1×	2	386
Sabine Neser Germany	4	386 0.9×	282 1.0×	200 0.9×	56 0.9×	58 1.1×	6	435
Ana Ayala United States	9	381 0.9×	270 1.0×	196 0.9×	59 1.0×	29 0.5×	16	474
Baha Alkuzweny United States	5	369 0.9×	255 0.9×	184 0.8×	54 0.9×	127 2.3×	7	459
Kamal Bouabdallah France	11	439 1.1×	350 1.3×	237 1.0×	66 1.1×	76 1.4×	27	531
Carola Boccomini Italy	8	390 0.9×	224 0.8×	106 0.5×	126 2.1×	76 1.4×	21	435
Abdulwahab J. Al-Tourah Canada	9	525 1.3×	364 1.3×	189 0.8×	98 1.7×	34 0.6×	18	616
Manfred Welslau Germany	7	335 0.8×	306 1.1×	228 1.0×	71 1.2×	49 0.9×	28	501
Ulrich von Gruenhagen Germany	10	421 1.0×	266 0.9×	289 1.3×	80 1.4×	14 0.3×	11	458
M. van ‘t Veer Netherlands	4	209 0.5×	161 0.6×	124 0.5×	32 0.5×	35 0.6×	5	278

Countries citing papers authored by Ursula Haak

Since Specialization

Citations

This map shows the geographic impact of Ursula Haak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ursula Haak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ursula Haak more than expected).

Fields of papers citing papers by Ursula Haak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ursula Haak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ursula Haak. The network helps show where Ursula Haak may publish in the future.

Co-authorship network of co-authors of Ursula Haak

This figure shows the co-authorship network connecting the top 25 collaborators of Ursula Haak. A scholar is included among the top collaborators of Ursula Haak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ursula Haak. Ursula Haak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

1.

Herold, Michael, Antje Haas, Stefanie Srock, et al.. (2007). Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology. 25(15). 1986–1992. 371 indexed citations

2.

Weide, Rudolf, Georg Heß, H. Köppler, et al.. (2007). High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leukemia & lymphoma. 48(7). 1299–1306. 75 indexed citations

3.

Weide, Rudolf, Georg Heß, Jochen Heymanns, et al.. (2006). High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).. Blood. 108(11). 2480–2480. 1 indexed citations

4.

Weide, Rudolf, Jochen Heymanns, H. Gamm, et al.. (2004). Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective and Well Tolerated Immuno-Chemotherapy for Relapsed and Refractory Indolent Lymphomas - Results of a Multicentre Phase-II-Study of the German Low Grade Lymphoma Study Group (GLSG).. Blood. 104(11). 2482–2482. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact